<DOC>
	<DOCNO>NCT01982331</DOCNO>
	<brief_summary>This phase I study evaluate safety vaccine protect influenza virus H2N2 subtype . A total 40 adult enrol receive two dos vaccine placebo one month apart .</brief_summary>
	<brief_title>Reactogenicity , Safety Immunogenicity Live Monovalent A/17/CALIFORNIA/66/395 ( H2N2 ) Influenza Vaccine</brief_title>
	<detailed_description>The aim study evaluate safety profile two intranasal dos LAIV A/17/California/66/395 ( H2N2 ) healthy adult Russia . A ( H2N2 ) viruses antigenically similar pandemic strain A/Singapore/1/57 , continue circulate domestic wild bird population , confirm routine moni¬toring avian influenza virus . 40 adult age 18-40 enrol . They randomize receive vaccine placebo . Blood urine collect week follow vaccination next vaccination monitor safety . Blood sample also collect several timepoints assess volunteer 's immune response vaccine . The total duration study 16 week volunteer .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Legal male female adult age 18 40 year Literate willing provide write informed consent . A sign informed consent . Free obvious health problem , establish medical history screening evaluation , include physical examination . Capable willing complete diary card willing return followup visit Willing comply rule isolation unit ( include willing able take oseltamivir influenza antiviral medication , recommend study physician ) . For female , willing take reliable birth control measure day 56 . Participation another clinical trial involve therapy within previous three month plan enrollment trial trial period . Receipt nonstudy vaccine within four week prior enrollment refusal postpone receipt vaccine four week study completion . Practice nasal irrigation regular basis within past six month engage nasal irrigation within two week prior enrollment . Recent history frequent nose bleeds ( &gt; 5 within past year ) . Clinically relevant abnormal paranasal anatomy . Recent history ( within past month ) rhino sinus surgery , surgery traumatic injury nose . Current recent ( within two week enrollment ) acute respiratory illness without fever . Other acute illness time study enrollment . Receipt immune globulin blood product within three month prior study enrollment plan receipt period subject participation study . Chronic administration ( define 14 consecutivelyprescribed day ) immunosuppressant and/or immunemodulating therapy within six month prior study enrollment . Participation previous trial H2N2 contain influenza vaccine . History asthma . Hypersensitivity previous administration influenza vaccine . History wheeze past receipt live influenza vaccine . Other AE follow immunization ( body temperature 40°C , collapse , nonfebrile seizure , anaphylaxis ) , least possibly relate previous receipt vaccine ( influenza ) . Suspected known hypersensitivity study vaccine component , include chicken egg protein . Seasonal ( autumnal ) hypersensitivity natural environment Acute chronic clinically significant pulmonary , cardiovascular , hepatic , metabolic , neurologic , psychiatric renal functional abnormality , determine medical history , physical examination clinical laboratory screening test , opinion investigator , might interfere study objective . Subjects physical examination finding clinical laboratory screening result would grade 2 high AE severity grade scale ( see Attachments ) exclude entry study exclude receipt dose two study vaccine placebo . History leukemia blood solid organ cancer . History thrombocytopenic purpura know bleed disorder . History seizure . Known suspect immunosuppressive immunodeficient condition kind , include HIV infection . Known chronic HBV HCV infection . Known tuberculosis infection evidence previous tuberculosis exposure . History chronic alcohol abuse and/or illegal drug use . Claustrophobia sociophobia . Pregnancy lactation . Any condition , opinion investigator , would increase health risk subject participates study would interfere evaluation study objective . Allergic , include anaphylactic , reaction introduction vaccine ( influenza ) subject 's medical history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>H2N2</keyword>
	<keyword>vaccine</keyword>
</DOC>